Protara Therapeutics Announces Promising Phase 2 Trial Results

Protara Therapeutics ( (TARA) ) has shared an update.

On December 3, 2025, Protara Therapeutics announced updated interim data from their Phase 2 ADVANCED-2 Trial of TARA-002, presented at the Society of Urologic Oncology Conference. The trial results showed promising complete response rates in BCG-Naïve NMIBC patients, with a 72% CR rate at any time and a favorable safety profile. The FDA has provided feedback supporting a registrational trial design for TARA-002 in BCG-Naïve patients, indicating potential expansion of its use beyond BCG-Unresponsive NMIBC. This development could significantly impact Protara’s market positioning and offer new treatment options for patients.

The most recent analyst rating on (TARA) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.

Spark’s Take on TARA Stock

According to Spark, TipRanks’ AI Analyst, TARA is a Underperform.

Protara Therapeutics faces considerable challenges typical in early-stage biotech, such as no revenue and persistent cash outflows. However, the strong equity and low debt levels provide some stability. The recent positive trial results are promising, but the stock remains high-risk due to its financial and operational metrics.

To see Spark’s full report on TARA stock, click here.

More about Protara Therapeutics

Protara Therapeutics is a biopharmaceutical company focused on developing treatments for non-muscle invasive bladder cancer (NMIBC) and other serious diseases. Their primary product, TARA-002, is being evaluated for its potential to treat NMIBC and lymphatic malformations.

Average Trading Volume: 587,685

Technical Sentiment Signal: Buy

Current Market Cap: $260.1M

For a thorough assessment of TARA stock, go to TipRanks’ Stock Analysis page.